Table 5. Haplotype Analysis of Tim-3 Polymorphisms with HBV Infection, HBsAg Seroclearance and HBV-Associated HCC.
| HBV Infection(freq) | HBsAg Seroclearance (freq) | HBV-Associated HCC (freq) | Healthy Control (freq) | P*(OR, 95%CI)a | P**(OR, 95%CI)b | P***(OR, 95%CI)c | |
| CAT*d | 21.16(0.053) | 20.57(0.051) | 2.37(0.006) | 0.01(0.000) | <0.001 (2139.7,132.85∼34463.6) | 0.907 (0.963,0.516∼1.797) | <0.001(0.107,0.028∼0.412) |
| CGC* | 13.59(0.034) | 26.41(0.066) | 19.06(0.048) | 17.22(0.043) | 0.496(0.778,0.376∼1.606) | 0.040(1.997,1.022∼3.902) | 0.327(1.425,0.700∼2.899) |
| CGT* | 51.05(0.128) | 39.55(0.099) | 84.11(0.210) | 79.65(0.199) | 0.006(0.584,0.398∼0.857) | 0.187(0.744,0.479∼1.156) | 0.002(1.825,1.248∼2.669) |
| TAC* | 21.36(0.053) | 13.45(0.034) | 8.13(0.020) | 10.80(0.027) | 0.059(2.023,0.960∼4.264) | 0.164(0.612,0.305∼1.229) | 0.013(0.368,0.162∼0.836) |
| TAT* | 110.28(0.276) | 103.52(0.259) | 119.04(0.298) | 131.06(0.328) | 0.098(0.774,0.571∼1.049) | 0.548(0.908,0.663∼1.243) | 0.488(1.115,0.820∼1.517) |
| TGC* | 118.85(0.297) | 146.67(0.367) | 129.35(0.323) | 113.86(0.285) | 0.729(1.056,0.777∼1.434) | 0.043(1.358,1.010∼1.826) | 0.417(1.133,0.838∼1.530) |
| TGT* | 57.51(0.144) | 46.36(0.116) | 31.48(0.079) | 39.28(0.098) | 0.051(1.535,0.996∼2.365) | 0.226(0.774,0.511∼1.172) | 0.003(0.508,0.321∼0.805) |
a
P* value was calculated between healthy controls and HBV Infection.
b
P** value was calculated between HBV Infection and HBsAg Seroclearance.
c
P*** value was calculated between HBV Infection and HBV-Associated HCC. P<0.05 was considered statistically significant.
d
Order of haplotype block: rs246871 (minor allele “C”), rs25855 (minor allele “A”), rs31223 (minor allele “C”).